Climb Bio, Inc. (CLYM)

Climb Bio's stock (CLYM) has gained approximately 229.58% in the past six months and 452.8% over the past 12 months. Key events impacting the stock price include pipeline progress announcements, financial results, presentations at investor conferences, analyst coverage and price target increases, and insider trading. The company announced pipeline progress and strategic priorities for 2026, which led to a +9.05% change. The company reported its Third Quarter 2025 financial results on November 6, 2025, and Fourth Quarter and Full Year 2025 financial results on March 5, 2026. Climb Bio presented at several investor conferences, including the Guggenheim's Emerging Outlook: Biotech Summit (February 12, 2026), Oppenheimer 36th Annual Healthcare Life Sciences Conference (February 25, 2026), and Leerink Global Healthcare Conference (March 9, 2026). Several financial firms initiated coverage or increased price targets for CLYM in March 2026, including B. Riley Financial, Raymond James Financial, and HC Wainwright. A director at Climb Bio sold 50,000 shares in planned trades on February 27, 2026.

As a clinical-stage biotechnology company, Climb Bio, Inc. does not currently have commercialized products or services, and therefore, traditional "demand seasonality" for its offerings is not applicable. The company's value and financial performance are primarily driven by its clinical development progress, regulatory milestones, and the potential future commercialization of its investigational therapies. Historically, April has shown the highest probability of positive returns for CLYM stock at 75.00%, while November has the lowest probability at 0.00%.

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases. The company's pipeline consists of monoclonal antibody product candidates, including Budoprutug, an anti-CD19 monoclonal antibody in Phase 2 trials for primary membranous nephropathy (pMN) and immune thrombocytopenia (ITP), and Phase 1b trials for systemic lupus erythematosus (SLE). Budoprutug has also been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of primary membranous nephropathy. CLYM116, an anti-APRIL monoclonal antibody, is in Phase 1 clinical trials for IgA nephropathy (IgAN) and other B-cell mediated diseases, with Climb Bio holding exclusive rights outside of Greater China.

Climb Bio, Inc. is headquartered in Wellesley Hills, Massachusetts, United States. The company has a global clinical development footprint with trial sites in multiple countries and a planned Phase 1b trial for budoprutug in China. The exclusive license for CLYM116 covers territories outside of Greater China, indicating a broader international focus.

Climb Bio's brand reputation in the past year is largely positive, driven by its clinical progress and potential in addressing immune-mediated diseases. The company has a consensus "Buy" rating from analysts, indicating confidence in its pipeline and long-term platform value. Consistent announcements of pipeline progress have contributed positively to its reputation. The company's focus on conditions with high unmet medical needs enhances its reputation as a company striving for meaningful patient impact. Its reported cash position as of September 2025 has reduced near-term dilution risk, which has positively influenced sentiment.

Climb Bio, Inc. has a mixed ownership structure comprising institutional, insider, and retail investors. Institutional investors hold approximately 53.64% to 72.56% of the company's stock, with Ra Capital Management, L.P. owning the most shares. Retail investors hold an estimated 19.66% to 36% of the company's stock. Insiders own approximately 13.15% to 24.12% of the stock, with Ai Eti LLC identified as the largest individual shareholder, owning 10.49% of the company.